Gefitinib in Lung Adenocarcinoma with Epidermal Growth Factor Receptor Mutation
Abstract
Introduction: Lung cancer continues to be the leading cause of death in the world, as well as in Cuba. More than 80% of EGFR epidermal growth factor receptor gene mutations are located in exons 19 and 21. Patients with EGFR mutations may benefit from treatment with tyrosine kinase inhibitors. TKIs (for its acronym in English), such as gefitinib, erlotinib, afatinib, osimertinib and dacomitinib with an objective response rate of more than 75% and a better quality of life compared to chemotherapy.
Objective: To describe the first case diagnosed with lung adenocarcinoma with EGFR mutation treated with gefitinib in the first line, at the Institute of Oncology and Radiobiology.
Clinical case: A 44-year-old female patient was diagnosed with lung adenocarcinoma with the presence of EGFR exon 19 mutation. It was staged as T3N3M1b stage IVB. He was treated with gefitinib achieving complete response, with progression-free survival of 17 months. She is maintained with better support measures until death.
Conclusions: Patients with lung adenocarcinoma with EGFR mutation, treated with gefitinib, achieve high response rates with a positive impact on survival.
Downloads
References
1. World Health Organization (WHO) Globocan, International Agency for Research on Cancer (IARC). 2020 [acceso 13/02/2023]. Disponible en: https://gco.iarc.fr/
2. Anuario Estadístico de Salud 2020, Dirección de Registros Médicos y Estadísticas de Salud Ministerio de Salud Pública de Cuba. La Habana. 2020; p 66 y 102 [acceso 13/02/2023] https://files.sld.cu/dne/files/2022/10/Anuario-Estadistico-de-Salud-2021.-Ed-2022.pdf
3. Li T, Kung H, Mack Ph and Gandara D. Genotyping and genomic profiling of Non-Small- Cell Lung Cancer: implication for current and future therapy. J ClinOncol. 2013;31(8):1039-49. DOI: 10.1200/JCO.2012.45.3753
4. Niederhuber JE, Armitage JO, Kastan MB, Doroshow JH y Tepper JEAbeloff. Oncologíaclínica. 6th edition. Editorial ElsevierEspaña. 2020.
5. DeVita VT, Rosenberg SA, Lawrence TS. Cancer Principles & Practice of Oncology. 12th edition. Editorial Wolters Kluwer. Holanda. 2023.
6. Arrieta O, Cardona AF, Martin C, Mas-Lopez L, Corrales-Rodriguez L, Bramaglia G, et al. Update frecuency of EGFR and KRAS mutations in Non-Small Cell Lung Cancer in Latin America. The Latin-Americam Consortium for the investigation of Lung cancer (CliCaP). J ThoracOncol. 2015;10(5):838-43. DOI: 10.1097/JTO.0000000000000481
7. Lee HJ, Jeong GH, Li H, Kim MS, KimJS, Park SJ, et al. Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer: systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2021;25(20):6232-244. DOI: 10.26355/eurrev_202110_26993
8. Siegel R, Miller K, andJemal A. Cancer Statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30. DOI: 10.3322/caac.21590
9. Hirsh V. Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors. Ther Adv Med Oncol. 2018; ; 10: 1758834017753338. DOI: 10.1177/1758834017753338
10. YonedaK, Imanishi N, Ichiki Yand Tanaka F. Treatment of Non-Small Cell Lung Cancer with EGFR-mutations. J UOEH. 2019;41(2):153-63. DOI: 10.7888/juoeh.41.153.
11. Sousa AC, Silveira C, Janeiro A, Malveiro S, Oliveira AR, Felizardo M et al. Detection of rare and novel EGFR mutations in NSCLC patients: Implications for treatment-decision. Lung Cancer. 2020;139:35-40. DOI: 10.1016/j.lungcan.2019.10.030
12. Li Y, Appius A, Pattipaka T, Feyereislova A, Cassidy A, Ganti AK. Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in the USA. PLoSOne. 2019;14(1):e0209709. DOI: 10.1371/journal. pone.0209709.
13. Dalurzo M, Aviles-Salas A, Soares F, HouY, Li Y, Stroganova A, et al. Testing for EGFR mutations and ALK rearrangements in Advanced Non-Small Cell Lung Cancer. Considerations for countries in emerging markets. Onco Targets and Therapy. 2021;14:4671-92. DOI: 10.2147/OTT.S313669
14. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Geftinib or Carboplatin–Paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947-57. DOI: 10.1056/NEJMoa0810699
15. Han JY, Park K, Kim SW, Lee DH, Kim HY, Kim HT, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinomaof the lung. J ClinOncol. 2012;30(10):1122-28. DOI: 10.1200/JCO.2011.36.8456
16. Wo H, He J, Zhao Y, Yu H, Chen F, Yi H. The efficacy and toxicity of Gefitinib in treating non-small cell lung cancer: a meta-analysis of 19 randomized clinical trial. J Cancer. 2018;9(8):1455-65. DOI: 10.7150/jca.23356
17. Zhou C, Wu YL, Chen G, Feng J, Liu X, Wang Ch, et al. Erlotinib versus chemotherapy as first -line treatment for patients with advanced EGFR mutation-positive non son small- cell lung cancer (OPTIMAL, CTONG-0802): a multicenter , open label , randomized, phase III study. LancertOncol. 2011;12(8):735-42. DOI: 10.1016/S1470-2045(11)70184-X
18. Rosell R, Caecereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first- line treatment for Europeanpatients with advanced EGFR mutation- positive non- small cell lung cancer (EURTAC): a multicenter, open –label, randomized phase 3 trial. LancetOncol. 2012;13(3):239-46. DOI: 10.1016/S1470-2045(11)70393-X
19. Keunchil Park, Tan EH, O’Byrne K, Zhang L, Boyer M, Mok T, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cáncer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol Published. 2016;17(5):577-89.DOI: 10.1016/S1470-2045(16)30033-X
20. Sharma N, Graziano S. Overviewof the LUX–Lung clinical trial program of afatinib for non-small cell lung cancer. Cancer Treat Rev. 2018; 69: 143-51. DOI: 10.1016/j.ctrv.2018.06.018
21. Tu HY, Wu YL. Afatinib for the first-line treatment of EGFR mutation-positive NSCLC in China: a review of clinical data. FutureOncol. 2020;16(31):2569-86.DOI: 10.2217/fon-2020-0320
22. Fujii H, Nagaku H, Kobayashi N, Kubo S, Tanaka K, Watanabe K, et al. Liquid biopsy for detecting epidermal growth factor receptor mutation among patients with non-small cell lung cancer treated with afatinib: a multicenter prospective study. BMC Cancer. 2022;22(1):1035. DOI: 10.1186/s12885-022-10135-z
23. Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or platinumpemetrexed in EGFR T790Mpositive lung cancer. N Engl J Med. 2017;376:629-40. DOI: 10.1056/NEJMoa1612674
24. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in Untreated EGFRMutated Advanced Non–SmallCell Lung Cancer. N Eng J Med. 2018;378:113125. DOI: 10.1056/NEJMoa1713137
25. Flores YI, Neninger E, Páramo DL, Ortiz R, Alfonso S, Alsina S, et al. Diagnóstico y tratamiento del cáncer de pulmón. Programa Integral para el control del Cáncer en Cuba. Cáncer de pulmón de células no pequeñas:7-12. Editorial Ciencias Médicas, 2020.
Downloads
Published
How to Cite
Issue
Section
License
Esta revista provee acceso libre e inmediato a su contenido bajo el principio de que hacer disponible gratuitamente la investigación al público apoya a un mayor intercambio de conocimiento global.
Esto significa que se permite su copia y distribución por cualquier medio siempre que mantenga el reconocimiento de sus autores, no haga uso comercial de las obras y no realice ninguna modificación de ellas.
El envío de manuscritos, el procesamiento y la publicación no ofrece ningún coste a los autores, es totalmente gratis.
